Proteome and Agilent expand their cooperative marketing agreement to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics analysis
Proteome Systems and Agilent Technologies announced the expansion of their cooperative marketing agreement to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics analysis.
Glycomics is the study of the structure and function of sugars.
Many diseases, such as cancer, arthritis and influenza cause changes to the sugars that are attached to proteins.
These changes in sugars can serve as highly accurate and powerful diagnostic biomarkers of the diseases.
Proteome Systems will use its globally recognized expertise in biomarker discovery to provide Agilent with glycomics applications and software development for use with Agilent's mass spectrometer range of instruments.
Agilent will provide its new, high-sensitivity HPLC/Chip-based 6240 Ion Trap LC/MS system for the mass spectrometric analysis of protein-associated glycans.
An earlier marketing agreement between Proteome Systems and Agilent was announced in April 2005.
"Changes in the glycosylation patterns of proteins in cancers are well-known indicators for the progression of the disease," said Nicolle Packer, Proteome Systems's programme leader in cancer proteomics.
"Our lead prostate cancer programme, in collaboration with US-based Egenix , will benefit enormously from the cooperative technology program with Agilent.
"We are confident that the glycomics community in general will benefit from the development of new instruments, software and tools.
"We have successfully worked in this area for many years and are well placed to provide complete analysis solutions to Agilent for this type of discovery application".
"Agilent aims to develop new LC and LC/MS technologies and workflows for biomarker discovery, glycan and PTM analysis," said Taia Ergueta, general manager of Agilent's Proteomics and LC/MS business.
"Proteome Systems brings extensive experience in glycomics and glycoprotein-based biomarkers.
"Together, we're uniquely poised to develop powerful, novel solutions."
